KR100647844B1 - 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 - Google Patents
인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 Download PDFInfo
- Publication number
- KR100647844B1 KR100647844B1 KR1020060062618A KR20060062618A KR100647844B1 KR 100647844 B1 KR100647844 B1 KR 100647844B1 KR 1020060062618 A KR1020060062618 A KR 1020060062618A KR 20060062618 A KR20060062618 A KR 20060062618A KR 100647844 B1 KR100647844 B1 KR 100647844B1
- Authority
- KR
- South Korea
- Prior art keywords
- prostate cancer
- cancer
- antigen
- cells
- cell line
- Prior art date
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 178
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 176
- 108091007433 antigens Proteins 0.000 title claims abstract description 143
- 102000036639 antigens Human genes 0.000 title claims abstract description 139
- 239000000427 antigen Substances 0.000 title claims abstract description 136
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000010171 animal model Methods 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 230000001024 immunotherapeutic effect Effects 0.000 title claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 title claims description 104
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 86
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims abstract description 47
- 241001465754 Metazoa Species 0.000 claims abstract description 36
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims abstract description 30
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims abstract description 30
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims abstract description 28
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims abstract description 27
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 210000002307 prostate Anatomy 0.000 claims abstract description 11
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 108010051457 Acid Phosphatase Proteins 0.000 claims abstract description 5
- 102000013563 Acid Phosphatase Human genes 0.000 claims abstract description 5
- 241000283984 Rodentia Species 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 208
- 201000011510 cancer Diseases 0.000 claims description 93
- 230000005907 cancer growth Effects 0.000 claims description 14
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 2
- 102100038358 Prostate-specific antigen Human genes 0.000 abstract description 46
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 241000699660 Mus musculus Species 0.000 abstract description 5
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 49
- 239000013598 vector Substances 0.000 description 26
- 229940029030 dendritic cell vaccine Drugs 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 238000011282 treatment Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 208000008839 Kidney Neoplasms Diseases 0.000 description 14
- 206010038389 Renal cancer Diseases 0.000 description 14
- 201000010982 kidney cancer Diseases 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 238000002619 cancer immunotherapy Methods 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 12
- 230000009401 metastasis Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 210000002798 bone marrow cell Anatomy 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- -1 PCA Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 4
- 101150056441 Pctp gene Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 230000001759 immunoprophylactic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000005904 anticancer immunity Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 108010031025 Alanine Dehydrogenase Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 208000014670 posterior cortical atrophy Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150003509 tag gene Proteins 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
타깃 유전자 | 프라이머 | 서열 |
PAP | PAP-XhoI/s | 5'-TACCCCTCGAGAAGGAGTTGAAGTTTGTGACT-3' |
PAP-HindⅢ/as | 5'-TACCCAAGCTTTTAATCTGTACTGTCCTCAGTAC-3' | |
PSA | PSA-XhoI/s | 5'-TACCCCTCGAGCCCCTCATCCTGTCTCGG-3' |
PSA-HindⅢ/as | 5'-TACCCAAGCTTTTAGGGGTTGGCCACGATGGT-3' | |
PSMA | PSMA-XhoI/s | 5'-TACCCCTCGAGGTTGTTCATGAAATTGTGAGG-3' |
PSMA-HindⅢ/as | 5'-TACCCAAGCTTTTATCCTGGGAATGACTCCCCT-3' | |
PCA | PCA-XhoI/s | 5'-TTGACCTCGAGCACGCGCCCTGGGACAAC-3' |
PCA-HindⅢ/as | 5'-TCTAAAAGCTTCTAGAGGCTGCAGGCCTCCTG-3' | |
PSCA | PSCA-XhoI/s | 5'-TTGACCTCGAGCAGCCAGGCACTGCCCTG-3' |
PSCA-HindⅢ/as | 5'-TCTAAAAGCTTCTACGGCTGCAGGGCATGG-3' |
타깃 유전자 | 프라이머 | 서열 |
PAP | PAP-HindⅢ/s | 5'-TACCCAAGCTTCGCCACCATGGGTAGAGCTGCACCCCTCCTC-3' |
PAP-XhoI/as | 5'-TACCCCTCGAGCCAGCATAATCTGGAACATCATATGGATAATCTGTACTGTCCTCAGTACC-3' | |
PSA | PSA-HindⅢ/s | 5'-TACCCATGCTTCGCCACCATGGGTGTCCCGGTTGTCTTCCTCA-3' |
PSA-XhoI/as | 5'-TACCCCTCGAGCCAGCATAATCTGGAACATCATATGGATAGGGGTTGGCCACGATGGT-3' | |
PSMA | PSMA-HindⅢ/s | 5'-TACCCAAGCTTCGCCACCATGGATTGGAATCTCCTTCACGAAAC-3' |
PSMA-XhoI/as | 5'-TACCCCTCGAGCCAGCATAATCTGGAACATCATATGGATATCCTGGGAATGACTCCCCT-3' | |
PCA | PCA-HindⅢ/s | 5'-TTGACAAGCTTCGCCACCATGGGAGCCCCGCTCGCCGTAG-3' |
PCA-XhoI/as | 5'-TCTAACTCGAGCCAGCATAGTCTGGGACGTCATATGGATAGAGGCTGCAGGCCTCCTG-3' | |
PSCA | PSCA-HindⅢ/s | 5'-TTGACAAGCTTCGCCACCATGGGAGCTGTGCTGCTTGCCCTGT-3' |
PSCA-XhoI/as | 5'-TCTAACTCGAGCCAGCATAGTCTGGGACGTCATATGGATAGTTGCACAAGTCGGTGTCAC-3' |
Claims (10)
- 다음의 단계를 포함하는 인간 전립선암 동물모델을 이용한 수지상세포-유래 전립선암 면역치료제의 전립선암 예방 효능을 분석하는 방법:(a) 분석 대상의 수지상 세포를 인간을 제외한 정상동물에게 투여하는 단계;(b) 상기 동물에게 인간 전립선암-특이 항원을 발현하는 암 세포주를 투여하는 단계; 및(c) 상기 동물에서 암 세포의 형성 또는 성장을 측정하여 수지상세포-유래 전립선암 면역치료제의 예방 효능을 결정하는 단계.
- 제 1 항에 있어서, 상기 동물은 설치류 동물인 것을 특징으로 하는 방법.
- 제 2 항에 있어서, 상기 설치류 동물은 마우스(Mus musculus)인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 인간 전립선암-특이 항원은 PCA(prostate cancer antigen), PSCA(prostate stem cell antigen), PSA(prostate-specific antigen), PAP(prostate acid phosphatase) 또는 PSMA(prostate-specific membrane antigen)인 것을 특징으로 하는 방법.
- 제 4 항에 있어서, 상기 인간 전립선암-특이 항원은 PAP인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 암 세포주는 마우스(Mus musculus)로부터 유래된 것을 특징으로 하는 방법.
- 제 6 항에 있어서, 상기 암 세포주는 상기 동물에 대하여 동종동질(syngeneic)의 세포인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (a)에서 수지상 세포의 투여의 투여는 피하 주입(subcutaneous injection) 방법으로 실시되는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (b)에서 암 세포주의 투여는 피하 주입(subcutaneous injection) 방법으로 실시되는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 인간 전립선암-특이 항원을 발현하는 암 세포주는 전립선암 세포주-유래가 아닌 것을 특징으로 하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060062618A KR100647844B1 (ko) | 2006-07-04 | 2006-07-04 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060062618A KR100647844B1 (ko) | 2006-07-04 | 2006-07-04 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050045236A Division KR100647847B1 (ko) | 2005-05-27 | 2005-05-27 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100647844B1 true KR100647844B1 (ko) | 2006-11-23 |
Family
ID=37712962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060062618A KR100647844B1 (ko) | 2006-07-04 | 2006-07-04 | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100647844B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101728483B1 (ko) | 2012-05-04 | 2017-04-19 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
-
2006
- 2006-07-04 KR KR1020060062618A patent/KR100647844B1/ko active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101728483B1 (ko) | 2012-05-04 | 2017-04-19 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
KR20190042760A (ko) * | 2012-05-04 | 2019-04-24 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
KR102125658B1 (ko) * | 2012-05-04 | 2020-06-22 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102049928B1 (ko) | 효모-muc1 면역요법 조성물 및 그 용도 | |
EP0551401B2 (en) | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity | |
US7339089B2 (en) | Transgenic animal expressing HLA-A24 and utilization thereof | |
Mukherjee et al. | Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred | |
JP5291641B2 (ja) | 癌抗原及びその利用 | |
EP0929318B1 (en) | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same | |
KR20010024585A (ko) | 종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도 | |
CA2351729A1 (en) | Cell surface receptor antigen vaccines | |
KR100647847B1 (ko) | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법 | |
KR100900742B1 (ko) | 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법 | |
US10576145B2 (en) | CD200 inhibitors and methods of use thereof | |
KR100647844B1 (ko) | 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 효능을 분석하는 방법 | |
CN101575607A (zh) | 一种基于人muc1重复序列与gm-csf融合表达的重组卡介苗疫苗 | |
EP2608802B1 (en) | Immunotherapeutic method for treating prostate cancer | |
JP5393661B2 (ja) | プレプロカルシトニン抗原tエピトープ | |
McLaughlin et al. | Cancer immunotherapy: insights from transgenic animal models | |
CN106350578A (zh) | Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用 | |
Fukui et al. | Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells | |
Wu et al. | Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer | |
Li et al. | Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice | |
JP4705697B2 (ja) | Mn/ca9由来のhla−a24拘束性腫瘍抗原ペプチド | |
AU2004237854B2 (en) | Melanoma cell lines expressing shared melanoma antigens and methods of using same | |
Hargadon | Melanoma immunotherapy: overcoming obstacles to augment anti-tumor immune responses | |
JP2009035534A (ja) | Hla−a24拘束性抗原ペプチドおよびその用途 | |
Turner | Regulation of MUC1-specific immunity by CD4+ T cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121114 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131112 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141017 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151027 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161109 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170920 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181112 Year of fee payment: 13 |